Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011737 | 0.83 | TAAR1 (0.56) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL2809450 | 0.83 | MAOB (0.56) | MAOB | |
| 3-Methoxybenxyl Isothiocyanate SCHEMBL1551644 | 0.83 | MIF (0.64) | TAAR1IDO1AGXTCMA1CTBP2 | |
| SCHEMBL29170708 | 0.82 | GRIN2D (0.46) | — | |
| SCHEMBL9490171 | 0.81 | TAAR1 (0.60) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL5465655 | 0.81 | MIF (0.47) | TAAR1CYP1A2 | |
| SCHEMBL26785 | 0.81 | MIF (0.47) | TAAR1CYP1A2 | |
| SCHEMBL3876902 | 0.81 | LMNA (0.54) | ACHE | |
| Chloromethane SCHEMBL15655633 | 0.80 | MIF (0.43) | TAAR1 | |
| SCHEMBL22471928 | 0.79 | MIF (0.46) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20070185148-A1 | M3 muscarinic acetylchoine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1745046-A2 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1725238-A2 | M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006079916-A1 | THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-12-08 | — | — | US | disclosed |
| WO-2005111038-A2 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005094251-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| WO-1999012912-A1 | THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | TAAR1 1097/4885IDO1 4724/4885AGXT 3405/4885 |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | CHRNA7, CHRNA1, CHRNA5 | TAAR1 245/4885IDO1 850/4885AGXT 3391/4885 |
| US-20070185148-A1 | M3 muscarinic acetylchoine receptor antagonists | CHRM3, CHRM2, CHRM5 | TAAR1 90/4885IDO1 1599/4885AGXT 1228/4885 |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | ITGB3, ITGA2, ITGAV | TAAR1 589/4885IDO1 2824/4885AGXT 4339/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | TAAR1 2114/4885IDO1 4802/4885AGXT 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.